Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to determine whether the protease-activated receptor 2 over-expressor mouse (PAR2OE) with topical house dust mite (HDM) application is a more comprehensive and clinically representative AD model.
|
31487753 |
2019 |
Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, β-carotene significantly suppressed protein expression of TNF-α, IL-1β, and MCP-1 and mRNA expression of TSLP, IL-6, IL-1β, IL-4, IL-5, and Par-2 in AD-like skin tissues.
|
31292344 |
2019 |
Eczema
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Itch, inflammation, and atopic dermatitis are associated with activation of PAR2.
|
30471839 |
2019 |
Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the skin, PAR2 has extensively documented effects in promoting Th2 inflammation and pruritus; and its role in atopic dermatitis continues to be thoroughly studied.
|
30972831 |
2019 |
Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we tested the ability of a cell-penetrating pepducin, PZ-235, to mitigate the potentially deleterious effects of PAR2 in models of atopic dermatitis.
|
30287285 |
2019 |
Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings may provide clues to understanding the pathological role of DhPKs in skin disorders in which PAR2 is known to be involved, such as atopic dermatitis, Netherton syndrome, and psoriasis.
|
29458120 |
2018 |
Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that immediate-type allergic reactions caused by mast cell degranulation and PAR-2 activation by proteases are involved in the scratching behaviour in this AD-like model.
|
28191683 |
2018 |
Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
These beneficial effects of EGF on AD may be mediated by EGF regulation of Th1/Th2-mediated cytokines, mast cell hyperplasia, and protease activated receptor-2 (PAR-2) and thymic stromal lymphopoietin (TSLP), which are triggers of AD.
|
30093649 |
2018 |
Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Drugs targeting the nonhistaminergic (PAR2/TRPA1) itch pathway and itch sensitization are promising for treating AD itch.
|
28614190 |
2017 |
Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upregulation of KLK5 and abnormal expression of desmoglein 1 (DSG1) and filaggrin, but not PAR2 were identified in AD skin.
|
28238749 |
2017 |
Eczema
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that the activation of PAR-2 on keratinocytes by HDM-derived serine proteases induces the production of ET-1 and MMP-9, and may contribute to the induction of pruritus in AD.
|
28586781 |
2017 |
Eczema
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that PAR-2 activation can augment inflammatory cytokine and chemokine expression in canine keratinocytes, and it may initiate allergic inflammation through the proteolytic activity of allergens in canine atopic dermatitis.
|
23465358 |
2013 |
Eczema
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fluorescence-activated cell sorter analysis confirmed PAR2-induced and NF-kappaB-mediated upregulation of ICAM-1 protein after 13 h. Moreover, increased expression of PAR2 was detected in KTC of patients with atopic dermatitis suggesting a role of PAR2 in human skin inflammation.
|
15654951 |
2005 |